aluates Reports

$ 0.0

Automative

Global Wet Age-Related Macular Degeneration Treatment Market Research Report 2025

Published Date: May 2025

Report Code: QYRE-Auto-22D13064

Global Wet Age Related Macular Degeneration Treatment Market Research Report 2023

BUY CHAPTERS

Global Wet Age-Related Macular Degeneration Treatment Market Research Report 2025

Code: QYRE-Auto-22D13064

Report

May 2025

Pages:77

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Roche

Novartis

Regeneron Pharmaceuticals

Bayer HealthCare

Kanghong Pharma

Wet Age-Related Macular Degeneration Treatment Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Wet Age-Related Macular Degeneration Treatment Market

The global market for Wet Age-Related Macular Degeneration Treatment was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

The most common treatment doctors use to slow vision loss from wet AMD is called anti-VEGF injections. These medicines help stop bleeding and leaking from blood vessels in the back of your eye. Most people with wet AMD will get anti-VEGF injections as their only treatment.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Wet Age-Related Macular Degeneration Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Wet Age-Related Macular Degeneration Treatment.

The Wet Age-Related Macular Degeneration Treatment market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Wet Age-Related Macular Degeneration Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Wet Age-Related Macular Degeneration Treatment manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Wet Age-Related Macular Degeneration Treatment Market Report

Report Metric	Details
Report Name	Wet Age-Related Macular Degeneration Treatment Market
CAGR	5%
Segment by Type	Lucentis Eylea Avastin Others
Segment by Application	Hospital Clinic Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Roche, Novartis, Regeneron Pharmaceuticals, Bayer HealthCare, Kanghong Pharma
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Wet Age-Related Macular Degeneration Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Wet Age-Related Macular Degeneration Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Wet Age-Related Macular Degeneration Treatment Market report?

Ans: The main players in the Wet Age-Related Macular Degeneration Treatment Market are Roche, Novartis, Regeneron Pharmaceuticals, Bayer HealthCare, Kanghong Pharma

What are the Application segmentation covered in the Wet Age-Related Macular Degeneration Treatment Market report?

Ans: The Applications covered in the Wet Age-Related Macular Degeneration Treatment Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the Wet Age-Related Macular Degeneration Treatment Market report?

Ans: The Types covered in the Wet Age-Related Macular Degeneration Treatment Market report are Lucentis, Eylea, Avastin, Others

Recommended Reports

Macular Degeneration

Ophthalmic Drugs

Anti-VEGF Therapy

1 Wet Age-Related Macular Degeneration Treatment Market Overview

1.1 Product Definition

1.2 Wet Age-Related Macular Degeneration Treatment by Type

1.2.1 Global Wet Age-Related Macular Degeneration Treatment Market Value Comparison by Type (2024 VS 2031)

1.2.2 Lucentis

1.2.3 Eylea

1.2.4 Avastin

1.2.5 Others

1.3 Wet Age-Related Macular Degeneration Treatment by Application

1.3.1 Global Wet Age-Related Macular Degeneration Treatment Market Value by Application (2024 VS 2031)

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Other

1.4 Global Wet Age-Related Macular Degeneration Treatment Market Size Estimates and Forecasts

1.4.1 Global Wet Age-Related Macular Degeneration Treatment Revenue 2020-2031

1.4.2 Global Wet Age-Related Macular Degeneration Treatment Sales 2020-2031

1.4.3 Global Wet Age-Related Macular Degeneration Treatment Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Wet Age-Related Macular Degeneration Treatment Market Competition by Manufacturers

2.1 Global Wet Age-Related Macular Degeneration Treatment Sales Market Share by Manufacturers (2020-2025)

2.2 Global Wet Age-Related Macular Degeneration Treatment Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Wet Age-Related Macular Degeneration Treatment Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Wet Age-Related Macular Degeneration Treatment, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Wet Age-Related Macular Degeneration Treatment, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Wet Age-Related Macular Degeneration Treatment, Product Type & Application

2.7 Global Key Manufacturers of Wet Age-Related Macular Degeneration Treatment, Date of Enter into This Industry

2.8 Global Wet Age-Related Macular Degeneration Treatment Market Competitive Situation and Trends

2.8.1 Global Wet Age-Related Macular Degeneration Treatment Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Wet Age-Related Macular Degeneration Treatment Players Market Share by Revenue

2.8.3 Global Wet Age-Related Macular Degeneration Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Wet Age-Related Macular Degeneration Treatment Market Scenario by Region

3.1 Global Wet Age-Related Macular Degeneration Treatment Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Wet Age-Related Macular Degeneration Treatment Sales by Region: 2020-2031

3.2.1 Global Wet Age-Related Macular Degeneration Treatment Sales by Region: 2020-2025

3.2.2 Global Wet Age-Related Macular Degeneration Treatment Sales by Region: 2026-2031

3.3 Global Wet Age-Related Macular Degeneration Treatment Revenue by Region: 2020-2031

3.3.1 Global Wet Age-Related Macular Degeneration Treatment Revenue by Region: 2020-2025

3.3.2 Global Wet Age-Related Macular Degeneration Treatment Revenue by Region: 2026-2031

3.4 North America Wet Age-Related Macular Degeneration Treatment Market Facts & Figures by Country

3.4.1 North America Wet Age-Related Macular Degeneration Treatment Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Wet Age-Related Macular Degeneration Treatment Sales by Country (2020-2031)

3.4.3 North America Wet Age-Related Macular Degeneration Treatment Revenue by Country (2020-2031)

3.4.4 United States

3.4.5 Canada

3.5 Europe Wet Age-Related Macular Degeneration Treatment Market Facts & Figures by Country

3.5.1 Europe Wet Age-Related Macular Degeneration Treatment Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Wet Age-Related Macular Degeneration Treatment Sales by Country (2020-2031)

3.5.3 Europe Wet Age-Related Macular Degeneration Treatment Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Wet Age-Related Macular Degeneration Treatment Market Facts & Figures by Region

3.6.1 Asia Pacific Wet Age-Related Macular Degeneration Treatment Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Wet Age-Related Macular Degeneration Treatment Sales by Region (2020-2031)

3.6.3 Asia Pacific Wet Age-Related Macular Degeneration Treatment Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Wet Age-Related Macular Degeneration Treatment Market Facts & Figures by Country

3.7.1 Latin America Wet Age-Related Macular Degeneration Treatment Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Wet Age-Related Macular Degeneration Treatment Sales by Country (2020-2031)

3.7.3 Latin America Wet Age-Related Macular Degeneration Treatment Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Wet Age-Related Macular Degeneration Treatment Market Facts & Figures by Country

3.8.1 Middle East and Africa Wet Age-Related Macular Degeneration Treatment Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Wet Age-Related Macular Degeneration Treatment Sales by Country (2020-2031)

3.8.3 Middle East and Africa Wet Age-Related Macular Degeneration Treatment Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Wet Age-Related Macular Degeneration Treatment Sales by Type (2020-2031)

4.1.1 Global Wet Age-Related Macular Degeneration Treatment Sales by Type (2020-2025)

4.1.2 Global Wet Age-Related Macular Degeneration Treatment Sales by Type (2026-2031)

4.1.3 Global Wet Age-Related Macular Degeneration Treatment Sales Market Share by Type (2020-2031)

4.2 Global Wet Age-Related Macular Degeneration Treatment Revenue by Type (2020-2031)

4.2.1 Global Wet Age-Related Macular Degeneration Treatment Revenue by Type (2020-2025)

4.2.2 Global Wet Age-Related Macular Degeneration Treatment Revenue by Type (2026-2031)

4.2.3 Global Wet Age-Related Macular Degeneration Treatment Revenue Market Share by Type (2020-2031)

4.3 Global Wet Age-Related Macular Degeneration Treatment Price by Type (2020-2031)

5 Segment by Application

5.1 Global Wet Age-Related Macular Degeneration Treatment Sales by Application (2020-2031)

5.1.1 Global Wet Age-Related Macular Degeneration Treatment Sales by Application (2020-2025)

5.1.2 Global Wet Age-Related Macular Degeneration Treatment Sales by Application (2026-2031)

5.1.3 Global Wet Age-Related Macular Degeneration Treatment Sales Market Share by Application (2020-2031)

5.2 Global Wet Age-Related Macular Degeneration Treatment Revenue by Application (2020-2031)

5.2.1 Global Wet Age-Related Macular Degeneration Treatment Revenue by Application (2020-2025)

5.2.2 Global Wet Age-Related Macular Degeneration Treatment Revenue by Application (2026-2031)

5.2.3 Global Wet Age-Related Macular Degeneration Treatment Revenue Market Share by Application (2020-2031)

5.3 Global Wet Age-Related Macular Degeneration Treatment Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Roche

6.1.1 Roche Company Information

6.1.2 Roche Description and Business Overview

6.1.3 Roche Wet Age-Related Macular Degeneration Treatment Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Roche Wet Age-Related Macular Degeneration Treatment Product Portfolio

6.1.5 Roche Recent Developments/Updates

6.2 Novartis

6.2.1 Novartis Company Information

6.2.2 Novartis Description and Business Overview

6.2.3 Novartis Wet Age-Related Macular Degeneration Treatment Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Novartis Wet Age-Related Macular Degeneration Treatment Product Portfolio

6.2.5 Novartis Recent Developments/Updates

6.3 Regeneron Pharmaceuticals

6.3.1 Regeneron Pharmaceuticals Company Information

6.3.2 Regeneron Pharmaceuticals Description and Business Overview

6.3.3 Regeneron Pharmaceuticals Wet Age-Related Macular Degeneration Treatment Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Regeneron Pharmaceuticals Wet Age-Related Macular Degeneration Treatment Product Portfolio

6.3.5 Regeneron Pharmaceuticals Recent Developments/Updates

6.4 Bayer HealthCare

6.4.1 Bayer HealthCare Company Information

6.4.2 Bayer HealthCare Description and Business Overview

6.4.3 Bayer HealthCare Wet Age-Related Macular Degeneration Treatment Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Bayer HealthCare Wet Age-Related Macular Degeneration Treatment Product Portfolio

6.4.5 Bayer HealthCare Recent Developments/Updates

6.5 Kanghong Pharma

6.5.1 Kanghong Pharma Company Information

6.5.2 Kanghong Pharma Description and Business Overview

6.5.3 Kanghong Pharma Wet Age-Related Macular Degeneration Treatment Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Kanghong Pharma Wet Age-Related Macular Degeneration Treatment Product Portfolio

6.5.5 Kanghong Pharma Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Wet Age-Related Macular Degeneration Treatment Industry Chain Analysis

7.2 Wet Age-Related Macular Degeneration Treatment Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Wet Age-Related Macular Degeneration Treatment Production Mode & Process Analysis

7.4 Wet Age-Related Macular Degeneration Treatment Sales and Marketing

7.4.1 Wet Age-Related Macular Degeneration Treatment Sales Channels

7.4.2 Wet Age-Related Macular Degeneration Treatment Distributors

7.5 Wet Age-Related Macular Degeneration Treatment Customer Analysis

8 Wet Age-Related Macular Degeneration Treatment Market Dynamics

8.1 Wet Age-Related Macular Degeneration Treatment Industry Trends

8.2 Wet Age-Related Macular Degeneration Treatment Market Drivers

8.3 Wet Age-Related Macular Degeneration Treatment Market Challenges

8.4 Wet Age-Related Macular Degeneration Treatment Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Roche

Novartis

Regeneron Pharmaceuticals

Bayer HealthCare

Kanghong Pharma

List of Tables

Table 1. Global Wet Age-Related Macular Degeneration Treatment Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Wet Age-Related Macular Degeneration Treatment Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Wet Age-Related Macular Degeneration Treatment Market Competitive Situation by Manufacturers in 2024

Table 4. Global Wet Age-Related Macular Degeneration Treatment Sales (K Units) of Key Manufacturers (2020-2025)

Table 5. Global Wet Age-Related Macular Degeneration Treatment Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Wet Age-Related Macular Degeneration Treatment Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Wet Age-Related Macular Degeneration Treatment Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Wet Age-Related Macular Degeneration Treatment Average Price (US$/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Wet Age-Related Macular Degeneration Treatment, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Wet Age-Related Macular Degeneration Treatment, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Wet Age-Related Macular Degeneration Treatment, Product Type & Application

Table 12. Global Key Manufacturers of Wet Age-Related Macular Degeneration Treatment, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Wet Age-Related Macular Degeneration Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Wet Age-Related Macular Degeneration Treatment as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Wet Age-Related Macular Degeneration Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Wet Age-Related Macular Degeneration Treatment Sales by Region (2020-2025) & (K Units)

Table 18. Global Wet Age-Related Macular Degeneration Treatment Sales Market Share by Region (2020-2025)

Table 19. Global Wet Age-Related Macular Degeneration Treatment Sales by Region (2026-2031) & (K Units)

Table 20. Global Wet Age-Related Macular Degeneration Treatment Sales Market Share by Region (2026-2031)

Table 21. Global Wet Age-Related Macular Degeneration Treatment Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Wet Age-Related Macular Degeneration Treatment Revenue Market Share by Region (2020-2025)

Table 23. Global Wet Age-Related Macular Degeneration Treatment Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Wet Age-Related Macular Degeneration Treatment Revenue Market Share by Region (2026-2031)

Table 25. North America Wet Age-Related Macular Degeneration Treatment Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Wet Age-Related Macular Degeneration Treatment Sales by Country (2020-2025) & (K Units)

Table 27. North America Wet Age-Related Macular Degeneration Treatment Sales by Country (2026-2031) & (K Units)

Table 28. North America Wet Age-Related Macular Degeneration Treatment Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Wet Age-Related Macular Degeneration Treatment Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Wet Age-Related Macular Degeneration Treatment Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Wet Age-Related Macular Degeneration Treatment Sales by Country (2020-2025) & (K Units)

Table 32. Europe Wet Age-Related Macular Degeneration Treatment Sales by Country (2026-2031) & (K Units)

Table 33. Europe Wet Age-Related Macular Degeneration Treatment Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Wet Age-Related Macular Degeneration Treatment Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Wet Age-Related Macular Degeneration Treatment Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Wet Age-Related Macular Degeneration Treatment Sales by Region (2020-2025) & (K Units)

Table 37. Asia Pacific Wet Age-Related Macular Degeneration Treatment Sales by Region (2026-2031) & (K Units)

Table 38. Asia Pacific Wet Age-Related Macular Degeneration Treatment Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Wet Age-Related Macular Degeneration Treatment Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Wet Age-Related Macular Degeneration Treatment Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Wet Age-Related Macular Degeneration Treatment Sales by Country (2020-2025) & (K Units)

Table 42. Latin America Wet Age-Related Macular Degeneration Treatment Sales by Country (2026-2031) & (K Units)

Table 43. Latin America Wet Age-Related Macular Degeneration Treatment Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Wet Age-Related Macular Degeneration Treatment Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Wet Age-Related Macular Degeneration Treatment Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Wet Age-Related Macular Degeneration Treatment Sales by Country (2020-2025) & (K Units)

Table 47. Middle East and Africa Wet Age-Related Macular Degeneration Treatment Sales by Country (2026-2031) & (K Units)

Table 48. Middle East and Africa Wet Age-Related Macular Degeneration Treatment Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Wet Age-Related Macular Degeneration Treatment Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Wet Age-Related Macular Degeneration Treatment Sales (K Units) by Type (2020-2025)

Table 51. Global Wet Age-Related Macular Degeneration Treatment Sales (K Units) by Type (2026-2031)

Table 52. Global Wet Age-Related Macular Degeneration Treatment Sales Market Share by Type (2020-2025)

Table 53. Global Wet Age-Related Macular Degeneration Treatment Sales Market Share by Type (2026-2031)

Table 54. Global Wet Age-Related Macular Degeneration Treatment Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Wet Age-Related Macular Degeneration Treatment Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Wet Age-Related Macular Degeneration Treatment Revenue Market Share by Type (2020-2025)

Table 57. Global Wet Age-Related Macular Degeneration Treatment Revenue Market Share by Type (2026-2031)

Table 58. Global Wet Age-Related Macular Degeneration Treatment Price (US$/Unit) by Type (2020-2025)

Table 59. Global Wet Age-Related Macular Degeneration Treatment Price (US$/Unit) by Type (2026-2031)

Table 60. Global Wet Age-Related Macular Degeneration Treatment Sales (K Units) by Application (2020-2025)

Table 61. Global Wet Age-Related Macular Degeneration Treatment Sales (K Units) by Application (2026-2031)

Table 62. Global Wet Age-Related Macular Degeneration Treatment Sales Market Share by Application (2020-2025)

Table 63. Global Wet Age-Related Macular Degeneration Treatment Sales Market Share by Application (2026-2031)

Table 64. Global Wet Age-Related Macular Degeneration Treatment Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Wet Age-Related Macular Degeneration Treatment Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Wet Age-Related Macular Degeneration Treatment Revenue Market Share by Application (2020-2025)

Table 67. Global Wet Age-Related Macular Degeneration Treatment Revenue Market Share by Application (2026-2031)

Table 68. Global Wet Age-Related Macular Degeneration Treatment Price (US$/Unit) by Application (2020-2025)

Table 69. Global Wet Age-Related Macular Degeneration Treatment Price (US$/Unit) by Application (2026-2031)

Table 70. Roche Company Information

Table 71. Roche Description and Business Overview

Table 72. Roche Wet Age-Related Macular Degeneration Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 73. Roche Wet Age-Related Macular Degeneration Treatment Product

Table 74. Roche Recent Developments/Updates

Table 75. Novartis Company Information

Table 76. Novartis Description and Business Overview

Table 77. Novartis Wet Age-Related Macular Degeneration Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 78. Novartis Wet Age-Related Macular Degeneration Treatment Product

Table 79. Novartis Recent Developments/Updates

Table 80. Regeneron Pharmaceuticals Company Information

Table 81. Regeneron Pharmaceuticals Description and Business Overview

Table 82. Regeneron Pharmaceuticals Wet Age-Related Macular Degeneration Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 83. Regeneron Pharmaceuticals Wet Age-Related Macular Degeneration Treatment Product

Table 84. Regeneron Pharmaceuticals Recent Developments/Updates

Table 85. Bayer HealthCare Company Information

Table 86. Bayer HealthCare Description and Business Overview

Table 87. Bayer HealthCare Wet Age-Related Macular Degeneration Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 88. Bayer HealthCare Wet Age-Related Macular Degeneration Treatment Product

Table 89. Bayer HealthCare Recent Developments/Updates

Table 90. Kanghong Pharma Company Information

Table 91. Kanghong Pharma Description and Business Overview

Table 92. Kanghong Pharma Wet Age-Related Macular Degeneration Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 93. Kanghong Pharma Wet Age-Related Macular Degeneration Treatment Product

Table 94. Kanghong Pharma Recent Developments/Updates

Table 95. Key Raw Materials Lists

Table 96. Raw Materials Key Suppliers Lists

Table 97. Wet Age-Related Macular Degeneration Treatment Distributors List

Table 98. Wet Age-Related Macular Degeneration Treatment Customers List

Table 99. Wet Age-Related Macular Degeneration Treatment Market Trends

Table 100. Wet Age-Related Macular Degeneration Treatment Market Drivers

Table 101. Wet Age-Related Macular Degeneration Treatment Market Challenges

Table 102. Wet Age-Related Macular Degeneration Treatment Market Restraints

Table 103. Research Programs/Design for This Report

Table 104. Key Data Information from Secondary Sources

Table 105. Key Data Information from Primary Sources

Table 106. Authors List of This Report

List of Figures

Figure 1. Product Picture of Wet Age-Related Macular Degeneration Treatment

Figure 2. Global Wet Age-Related Macular Degeneration Treatment Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Wet Age-Related Macular Degeneration Treatment Market Share by Type: 2024 & 2031

Figure 4. Lucentis Product Picture

Figure 5. Eylea Product Picture

Figure 6. Avastin Product Picture

Figure 7. Others Product Picture

Figure 8. Global Wet Age-Related Macular Degeneration Treatment Market Value by Application (2020-2031) & (US$ Million)

Figure 9. Global Wet Age-Related Macular Degeneration Treatment Market Share by Application: 2024 & 2031

Figure 10. Hospital

Figure 11. Clinic

Figure 12. Other

Figure 13. Global Wet Age-Related Macular Degeneration Treatment Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global Wet Age-Related Macular Degeneration Treatment Market Size (2020-2031) & (US$ Million)

Figure 15. Global Wet Age-Related Macular Degeneration Treatment Sales (2020-2031) & (K Units)

Figure 16. Global Wet Age-Related Macular Degeneration Treatment Average Price (US$/Unit) & (2020-2031)

Figure 17. Wet Age-Related Macular Degeneration Treatment Report Years Considered

Figure 18. Wet Age-Related Macular Degeneration Treatment Sales Share by Manufacturers in 2024

Figure 19. Global Wet Age-Related Macular Degeneration Treatment Revenue Share by Manufacturers in 2024

Figure 20. Global 5 and 10 Largest Wet Age-Related Macular Degeneration Treatment Players: Market Share by Revenue in Wet Age-Related Macular Degeneration Treatment in 2024

Figure 21. Wet Age-Related Macular Degeneration Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 22. Global Wet Age-Related Macular Degeneration Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 23. North America Wet Age-Related Macular Degeneration Treatment Sales Market Share by Country (2020-2031)

Figure 24. North America Wet Age-Related Macular Degeneration Treatment Revenue Market Share by Country (2020-2031)

Figure 25. United States Wet Age-Related Macular Degeneration Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 26. Canada Wet Age-Related Macular Degeneration Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 27. Europe Wet Age-Related Macular Degeneration Treatment Sales Market Share by Country (2020-2031)

Figure 28. Europe Wet Age-Related Macular Degeneration Treatment Revenue Market Share by Country (2020-2031)

Figure 29. Germany Wet Age-Related Macular Degeneration Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. France Wet Age-Related Macular Degeneration Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. U.K. Wet Age-Related Macular Degeneration Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Italy Wet Age-Related Macular Degeneration Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. Russia Wet Age-Related Macular Degeneration Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. Asia Pacific Wet Age-Related Macular Degeneration Treatment Sales Market Share by Region (2020-2031)

Figure 35. Asia Pacific Wet Age-Related Macular Degeneration Treatment Revenue Market Share by Region (2020-2031)

Figure 36. China Wet Age-Related Macular Degeneration Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. Japan Wet Age-Related Macular Degeneration Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. South Korea Wet Age-Related Macular Degeneration Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. India Wet Age-Related Macular Degeneration Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Australia Wet Age-Related Macular Degeneration Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. China Taiwan Wet Age-Related Macular Degeneration Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Southeast Asia Wet Age-Related Macular Degeneration Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Latin America Wet Age-Related Macular Degeneration Treatment Sales Market Share by Country (2020-2031)

Figure 44. Latin America Wet Age-Related Macular Degeneration Treatment Revenue Market Share by Country (2020-2031)

Figure 45. Mexico Wet Age-Related Macular Degeneration Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Brazil Wet Age-Related Macular Degeneration Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Argentina Wet Age-Related Macular Degeneration Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Middle East and Africa Wet Age-Related Macular Degeneration Treatment Sales Market Share by Country (2020-2031)

Figure 49. Middle East and Africa Wet Age-Related Macular Degeneration Treatment Revenue Market Share by Country (2020-2031)

Figure 50. Turkey Wet Age-Related Macular Degeneration Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. Saudi Arabia Wet Age-Related Macular Degeneration Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. UAE Wet Age-Related Macular Degeneration Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. Global Sales Market Share of Wet Age-Related Macular Degeneration Treatment by Type (2020-2031)

Figure 54. Global Revenue Market Share of Wet Age-Related Macular Degeneration Treatment by Type (2020-2031)

Figure 55. Global Wet Age-Related Macular Degeneration Treatment Price (US$/Unit) by Type (2020-2031)

Figure 56. Global Sales Market Share of Wet Age-Related Macular Degeneration Treatment by Application (2020-2031)

Figure 57. Global Revenue Market Share of Wet Age-Related Macular Degeneration Treatment by Application (2020-2031)

Figure 58. Global Wet Age-Related Macular Degeneration Treatment Price (US$/Unit) by Application (2020-2031)

Figure 59. Wet Age-Related Macular Degeneration Treatment Value Chain

Figure 60. Channels of Distribution (Direct Vs Distribution)

Figure 61. Bottom-up and Top-down Approaches for This Report

Figure 62. Data Triangulation

Figure 63. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Ophthalmology for Age related Macular Degeneration Diseases Market Research Report 2024

Global Retinal Disorders Treatment Market Research Report 2024

Retinal Degenerative Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Retinal Degenerative Disease Treatment Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Anti vascular Endothelial Growth Factor Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Macular Degeneration Treatment Market Research Report 2024

Global Anti VEGF Drugs for the Treatment of Wet AMD Market Research Report 2024

Global Macular Degeneration AMD and Other Retinal Diseases Market Research Report 2024

Global Ranibizumab Injection Market Research Report 2024

Macular Degeneration Drug Pipeline Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Intensive Anti Aging Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions